Wuhan Keqian Biology Co Ltd
688526
Company Profile
Business description
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
Contact
No. 419, Gaoxin 2nd Road
Donghu New Technology Development Zone
Hubei Province
Wuhan430073
CHNT: +86 2781322942
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
924
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,636.18 | 3.19 | 0.01% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,185.87 | 87.57 | 0.42% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,382.88 | 12.02 | 0.19% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |